Notch信号通路在腺样囊性癌中的研究进展

doi:10.13701/j.cnki.kqyxyj.2023.12.003

口腔医学研究 ›› 2023, Vol. 39 ›› Issue (12): 1042-1045.DOI: 10.13701/j.cnki.kqyxyj.2023.12.003

Notch信号通路在腺样囊性癌中的研究进展

李芷, 陈伟^*

南京医科大学附属金陵医院,中国人民解放军东部战区总医院口腔科江苏南京 210016

收稿日期:2023-03-13 出版日期:2023-12-28 发布日期:2023-12-25
通讯作者: * 陈伟,E-mail:rollphy@aliyun.com
作者简介:李芷(1992~ ),女,安徽亳州人,主治医师,博士在读,主要从事口腔颌面部肿瘤学相关研究。
基金资助:
江苏省“科教强卫工程”青年医学人才项目(编号:QNRC2016907)

Notch Signaling Pathway in Adenoid Cystic Carcinoma: A Review

LI Zhi, CHEN Wei^*

Department of Stomatology, Jinling Hospital of Nanjing Medical University, General Hospital of Eastern Theater Command, PLA, Nanjing 210016, China

Received:2023-03-13 Online:2023-12-28 Published:2023-12-25

摘要/Abstract

摘要： 腺样囊性癌是一种较为罕见的分泌腺恶性肿瘤,最好发于涎腺。它具有嗜神经侵袭和早期血行转移的特征,这是其临床治疗的难点。近年来研究发现,Notch信号通路的异常激活在腺样囊性癌的发展和转移中具有重要的作用,Notch通路成员有望作为腺样囊性癌的预后指标和药物靶点。本文就Notch信号通路在腺样囊性癌中的调控作用和靶向药物研究进展做一综述。

关键词: 腺样囊性癌, Notch信号通路, 预后生物指标, 靶向治疗

Abstract: Adenoid cystic carcinoma is a rare kind of malignancy in secretory glands, usually occurs in salivary glands. It is characterized by perineural invasion and early hematogenous metastasis, presenting difficulties to its clinical treatment. Recent studies have found that Notch signaling pathway plays an important role in the development and metastasis of adenoid cystic carcinoma, and presents attractive prognostic indicators and drug targets. This article reviews the research progress of regulatory mechanisms and drug targets in adenoid cystic carcinoma based on Notch signaling pathway.

Key words: adenoid cystic carcinoma, Notch signaling pathway, prognostic biomarker, targeted therapy

李芷, 陈伟. Notch信号通路在腺样囊性癌中的研究进展[J]. 口腔医学研究, 2023, 39(12): 1042-1045.

LI Zhi, CHEN Wei. Notch Signaling Pathway in Adenoid Cystic Carcinoma: A Review[J]. Journal of Oral Science Research, 2023, 39(12): 1042-1045.

参考文献

[1] Dewenter I, Otto S, Kakoschke TK, et al. Recent advances, systemic therapy, and molecular targets in adenoid cystic carcinoma of the head and neck [J]. J Clin Med, 2023, 12(4): 1463.
[2] Ferreira A, Aster JC. Notch signaling in cancer: Complexity and challenges on the path to clinical translation [J]. Semin Cancer Biol, 2022, 85: 95-106.
[3] Xia R, Xu M, Yang J, et al. The role of Hedgehog and Notch signaling pathway in cancer [J]. Mol Biomed, 2022, 3(1): 44.
[4] Parikh AS, Wizel A, Davis D, et al. Single-cell RNA sequencing identifies a paracrine interaction that may drive oncogenic notch signaling in human adenoid cystic carcinoma [J]. Cell Rep, 2022, 41(9): 111743.
[5] Wang Y, Sun B, Zhang C, et al. Genetic heterogeneity and therapeutic target detection through microdissection in solid-type adenoid cystic carcinoma [J]. Pathology, 2022, 54(5): 580-590.
[6] Xie M, Wei S, Wu X, et al. Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival [J]. Lung Cancer, 2018, 121: 41-47.
[7] Xie J, Lin LS, Huang XY, et al. The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells [J]. Int J Biol Sci, 2020, 16(4): 598-610.
[8] Huang XY, Gan RH, Xie J, et al. The oncogenic effects of HES1 on salivary adenoid cystic carcinoma cell growth and metastasis [J]. BMC Cancer, 2018, 18(1): 436.
[9] Anjum S, Sen S, Pushker N, et al. Prognostic impact of Notch1 receptor and clinicopathological High-Risk Predictors in lacrimal gland adenoid cystic carcinoma [J]. Acta Ophthalmol, 2021, 99(8): e1467-e1473.
[10] Li Z, Zhang Q, Su H, et al. miR-5191 acts as a tumor suppressor in salivary adenoid cystic carcinoma by targeting Notch-2 [J]. Oral Dis, 2022, 28(7): 1871-1881.
[11] Wang K, Fan HY, Pang X, et al. Dll4/Notch1 signalling pathway is required in collective invasion of salivary adenoid cystic carcinoma [J]. Oncol Rep, 2021, 45(3): 1011-1022.
[12] Masse J, Truntzer C, Boidot R, et al. Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations [J]. Mod Pathol, 2020, 33(6): 1041-1055.
[13] Wang Y, Han Y, Xu SM, et al. Targeting EGFR enriches stem cell-like properties in salivary adenoid cystic carcinoma by activating the Notch1 pathway [J]. Cancer Manag Res, 2020, 12: 6655-6663.
[14] Feeney L, Hapuarachi B, Adderley H, et al. Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation [J]. Oral Oncol, 2022, 133: 106028.
[15] You WK, Schuetz TJ, Lee SH. Targeting the DLL/Notch signaling pathway in cancer: Challenges and advances in clinical development [J]. Mol Cancer Ther, 2023, 22(1): 3-11.
[16] Mccaw TR, Inga E, Chen H, et al. Gamma secretase inhibitors in cancer: A current perspective on clinical performance [J]. Oncologist, 2021, 26(4): e608-e621.
[17] Lee RH, Wai KC, Chan JW, et al. Approaches to the management of metastatic adenoid cystic carcinoma [J]. Cancers (Basel), 2022, 14(22): 5698.
[18] Ferrarotto R, Mishra V, Herz E, et al. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling [J]. Cell Death Dis, 2022, 13(8): 678.
[19] Kieran R, De Paula BHR, Hubank M, et al. Response of NOTCH1-activated tracheal adenoid cystic carcinoma to the gamma secretase inhibitor nirogacestat [J]. JCO Precis Oncol, 2021, 5: 1579-1583.
[20] Miller LE, Au V, Mokhtari TE, et al. A contemporary review of molecular therapeutic targets for adenoid cystic carcinoma [J]. Cancers (Basel), 2022, 14(4): 992.
[21] Smith DC, Chugh R, Patnaik A, et al. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors [J]. Invest New Drugs, 2019, 37(4): 722-730.
[22] Spriano F, Tarantelli C, Arribas AJ, et al. In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103 [J]. Br J Haematol, 2023, 200(5): 669-672.
[23] Lehal R, Zaric J, Vigolo M, et al. Pharmacological disruption of the Notch transcription factor complex [J]. Proc Natl Acad Sci U S A, 2020, 117(28): 16292-16301.
[24] Arai MA, Akamine R, Tsuchiya A, et al. The Notch inhibitor cowanin accelerates nicastrin degradation [J]. Sci Rep, 2018, 8(1): 5376.
[25] Hashemi M, Hasani S, Hajimazdarany S, et al. Non-coding RNAs targeting notch signaling pathway in cancer: From proliferation to cancer therapy resistance [J]. Int J Biol Macromol, 2022, 222(Pt A): 1151-1167.
[26] 谢茜,赵云,刘蓉,等.超声微泡介导的miRNA递送在恶性肿瘤治疗中的应用[J].生命的化学, 2020, 40(12): 2193-2199.
[27] 井汇源,曹素芳,刘影,等.基于RNA病毒的microRNA递送载体研究进展[J].生命的化学, 2021, 41(3): 519-525.
[28] Valcourt DM, Dang MN, Wang J, et al. Nanoparticles for manipulation of the developmental Wnt, Hedgehog, and Notch signaling pathways in cancer [J]. Ann Biomed Eng, 2020, 48(7): 1864-1884.

Notch信号通路在腺样囊性癌中的研究进展

Notch Signaling Pathway in Adenoid Cystic Carcinoma: A Review

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

[1]	张艳宁, 石宏, 李荷香, 王洁, 郝亚丽, 王旭, 袁云云. SDC4在唾液腺腺样囊性癌神经侵袭中的作用研究[J]. 口腔医学研究, 2023, 39(12): 1085-1091.
[2]	宗颖睿, 秦红霞, 候珍珍, 李晓娜, 胡文彬, 张晨. 术前免疫炎症指数和列线图对腺样囊性癌患者预后的预测价值[J]. 口腔医学研究, 2022, 38(12): 1128-1133.
[3]	卢浩, 徐万林, 吴一凡, 朱云, 刘胜文, 杨雯君. MUC1通过调控EGFR/ERK信号通路促进唾液腺腺样囊性癌细胞增殖和侵袭的研究[J]. 口腔医学研究, 2022, 38(1): 24-29.
[4]	朱永翠, 翟蕾, 闫亚姿, 李亚如. 过表达ADAM10通过调控Notch信号通路对牙周膜干细胞成骨分化的影响[J]. 口腔医学研究, 2021, 37(5): 468-473.
[5]	胡勤刚, 赵星星. 口腔鳞状细胞癌肿瘤相关成纤维细胞的研究进展[J]. 口腔医学研究, 2020, 36(4): 309-313.
[6]	邹会会, 徐文光, 尹西腾, 韩伟, 江琳琳. 基于SEER数据库分析影响大唾液腺腺样囊性癌患者预后的临床病理因素[J]. 口腔医学研究, 2020, 36(2): 167-171.
[7]	孙宏晨,李杏. 纳米载药系统靶向肿瘤相关巨噬细胞用于肿瘤治疗的研究进展[J]. 口腔医学研究, 2019, 35(6): 511-516.
[8]	徐川,李亚楠,谯丹,古欢,钟罗,吴键,于涛. MicroRNA-9影响涎腺腺样囊性癌侵袭能力的分子机制研究[J]. 口腔医学研究, 2019, 35(6): 563-567.
[9]	侯国玲, 姚瑶, 万光勇. 槲皮素对ACC-M细胞裸鼠移植瘤抑瘤效果的体内实验研究[J]. 口腔医学研究, 2018, 34(5): 554-557.
[10]	裴浩, 夏冬景, 黄莹莹. STAT6在涎腺腺样囊性癌组织中的表达及对细胞增殖和侵袭的影响[J]. 口腔医学研究, 2018, 34(11): 1212-1216.
[11]	靳勇勇. 整合素连接激酶和基质金属蛋白酶-9在涎腺腺样囊性癌中的表达及意义[J]. 口腔医学研究, 2016, 32(7): 764-767.